Qiagen (NYSE:QGEN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Qiagen (NYSE:QGEN - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven research firms that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $50.12.

QGEN has been the subject of a number of analyst reports. HSBC cut shares of Qiagen from a "buy" rating to a "hold" rating and set a $49.00 price objective for the company. in a research note on Thursday, October 17th. Robert W. Baird upped their price target on shares of Qiagen from $49.00 to $52.00 and gave the company an "outperform" rating in a report on Friday, August 2nd. Finally, Hsbc Global Res upgraded Qiagen to a "hold" rating in a research note on Thursday, October 17th.

Qiagen Stock Down 0.1 %

QGEN traded down $0.05 during trading on Friday, reaching $41.55. 492,400 shares of the stock traded hands, compared to its average volume of 1,179,280. The stock's 50-day simple moving average is $44.68 and its two-hundred day simple moving average is $43.54. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.46. Qiagen has a fifty-two week low of $34.74 and a fifty-two week high of $47.44. The stock has a market cap of $9.48 billion, a price-to-earnings ratio of 27.89, a price-to-earnings-growth ratio of 3.22 and a beta of 0.39.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.52 by $0.03. The business had revenue of $496.00 million during the quarter, compared to analysts' expectations of $495.45 million. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The firm's quarterly revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.53 EPS. As a group, equities research analysts expect that Qiagen will post 2.15 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of QGEN. Massmutual Trust Co. FSB ADV boosted its holdings in Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company's stock valued at $39,000 after purchasing an additional 243 shares in the last quarter. CWM LLC grew its holdings in shares of Qiagen by 12.0% in the 2nd quarter. CWM LLC now owns 2,505 shares of the company's stock worth $103,000 after purchasing an additional 269 shares during the last quarter. Private Advisor Group LLC increased its position in shares of Qiagen by 8.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,251 shares of the company's stock worth $285,000 after purchasing an additional 461 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Qiagen by 806.5% during the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company's stock worth $26,000 after purchasing an additional 500 shares in the last quarter. Finally, Sequoia Financial Advisors LLC lifted its holdings in Qiagen by 2.8% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 18,618 shares of the company's stock valued at $848,000 after purchasing an additional 511 shares during the last quarter. 70.00% of the stock is owned by institutional investors.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.